Skip to content
Newcastle Biomedical Research Centre
  • About
    • Our Vision and Strategy
      • Equality, Diversity and Inclusion
    • Our Governance
    • Our People
      • Leadership Team
      • Research Theme Leads
      • Public Partnership Advisory Group (PPAG)
      • Cross-Cutting Area Leads
      • Core Theme
      • Trainees
    • Our Partnership
    • Our Region
    • National Initiatives
    • Acknowledgement and Branding
  • Our Research
    • Ageing, Sarcopenia and Multimorbidity
      • The Theme
      • Team
      • Impact
      • News and Events
    • Dementia, Mental Health and Neurodegeneration
      • The Theme
      • Team
      • Impact
      • News and Events
      • Lewy Body Dementia Doctoral Training Network
    • Digital Health, Ageing Innovation and Inclusion
      • The Theme
      • Team
      • Impact
      • News and Events
      • Patient and Public Involvement and Engagement
    • Informatics and Precision Care for an Ageing Population
      • The Theme
      • Team
      • Impact
      • News and Events
    • Liver Disease, Multimorbidity and Lifestyle
      • The Theme
      • Team
      • Impact
      • News and Events
    • Musculoskeletal Disease and Inflammation Medicine
      • The Theme
      • Team
      • Impact
      • News and Events
      • PIMS
    • Neuromuscular Disease, Rare Diseases and Mitochondrial Dysfunction
      • The Theme
      • Team
      • Impact
      • News and Events
    • Skin Disease, Oral Disease and Immunogenomics
      • The Theme
      • Team
      • Impact
      • News and Events
    • Interdisciplinary Research
  • Patient & Public Involvement
    • Get Involved in Research
    • Public Partnership Advisory Group
    • PPIE Resources for Researchers
  • Industry & Partners
  • Training & Professional Development
    • Our Research Training
    • Resource Hub
    • Opportunities
  • Our Impact
  • News and Events
  • Contact
Back to top Go to content
Newcastle Biomedical Research Centre Logo
  • About
    • Our Vision and Strategy
    • Our Governance
    • Our People
    • Our Partnership
    • Our Region
    • National Initiatives
    • Acknowledgement and Branding
  • Our Research
    • Ageing, Sarcopenia and Multimorbidity
    • Dementia, Mental Health and Neurodegeneration
    • Digital Health, Ageing Innovation and Inclusion
    • Informatics and Precision Care for an Ageing Population
    • Liver Disease, Multimorbidity and Lifestyle
    • Musculoskeletal Disease and Inflammation Medicine
    • Neuromuscular Disease, Rare Diseases and Mitochondrial Dysfunction
    • Skin Disease, Oral Disease and Immunogenomics
    • Interdisciplinary Research
  • Patient & Public Involvement
    • Get Involved in Research
    • Public Partnership Advisory Group
    • PPIE Resources for Researchers
  • Industry & Partners
  • Training & Professional Development
    • Our Research Training
    • Resource Hub
    • Opportunities
  • Our Impact
  • News and Events
  • Contact

Liver Disease, Multimorbidity
and Lifestyle

  1. Our Research
  2. Liver Disease, Multimorbidity and Lifestyle
  3. The Theme

Chronic liver disease is a major cause of poor quality of life and is a contributor to excess death, making it a significant concern for both patients and the NHS.

In our liver disease theme, we explore the contribution that the ageing process makes to the biology of liver disease. To do this, we harness the expertise of Newcastle’s world-class ageing biology research.

Theme co-leads are; Quentin Anstee, Professor of Experimental Hepatology and an Honorary Consultant Hepatologist at Newcastle Hospitals. He leads one of the largest MASLD clinical services in the UK.

And Helen Reeves, Professor of Liver Cancer and an Honorary Consultant Hepatologist at Newcastle Hospitals. She leads care for patients with liver disease and cancer in the UK.

 

What we cover in this theme

Newcastle BRC’s Liver Disease Theme studies the following conditions:

  • Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)
  • Hepatocellular Carcinoma (HCC)
  • Primary Biliary Cholangitis (PBC)
  • Auto immune hepatitis (AIH)

We are researching the mechanisms behind these conditions in order to find treatments that can improve the quality life and survival of those affected.  

Published Papers

  • CXCR2 inhibition enables NASH-HCC immunotherapy

    CXCR2 inhibition enables NASH-HCC immunotherapy

    Journal: Gut. 2022 2022: 71(10):2093–106. doi.org/10.1136/gutjnl-2021-326259

    Authors: Leslie J, Mackey JBG, Jamieson T, Ramon-Gil E, Drake TM, Fercoq F, Clark W, Gilroy K, Hedley A, Nixon C, Luli S, Laszczewska M, Pinyol R, Esteban-Fabró R, Willoughby CE, Haber PK, Andreu-Oller C, Rahbari M, Fan C, Pfister D, Raman S, Wilson N, Müller M, Collins A, Geh D, Fuller A, McDonald D, Hulme G, Filby A, Cortes-Lavaud X, Mohamed NE, Ford CA, Raffo Iraolagoitia XL, McFarlane AJ, McCain MV, Ridgway RA, Roberts EW, Barry ST, Graham GJ, Heikenwälder M, Reeves HL, Llovet JM, Carlin LM, Bird TG, Sansom OJ, Mann DA.

    Read Paper

  • A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures

    A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures

    Journal: NNature Metabolism. 2023 Apr;5(4):572-578. doi.org/10.1038/s42255-023-00775-1

    Authors: ovaere O, Hasoon M, Alexander L, Cockell S, Tiniakos D, Ekstedt M, Schattenberg JM, Boursier J, Bugianesi E, Ratziu V; LITMUS Investigators; Daly AK, Anstee QM

    Read Paper

  • Human-correlated genetic models identify precision therapy for liver cancer

    Human-correlated genetic models identify precision therapy for liver cancer

    Journal: Nature. 2025 Mar;639(8055):754-764. doi.org/10.1038/s41586-025-08585-z


    Authors: Müller M, May S, Hall H, Kendall TJ, McGarry L, Blukacz L, Nuciforo S, Georgakopoulou A, Jamieson T, Phinichkusolchit N, Dhayade S, Suzuki T, Huguet-Pradell J, Powley IR, Officer-Jones L, Pennie RL, Esteban-Fabró R, Gris-Oliver A, Pinyol R, Skalka GL, Leslie J, Hoare M, Sprangers J, Malviya G, Mackintosh A, Johnson E, McCain M, Halpin J, Kiourtis C, Nixon C, Clark G, Clark W, Shaw R, Hedley A, Drake TM, Tan EH, Neilson M, Murphy DJ, Lewis DY, Reeves HL, Le Quesne J, Mann DA, Carlin LM, Blyth K, Llovet JM, Heim MH, Sansom OJ, Miller CJ, Bird TG

    Read Paper

  • Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study

    Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study

    Journal: Lancet Gastroenterol Hepatol. 2025 Oct;10(10):924-940. doi.org/10.1016/s2468-1253(25)00128-1

    Authors: Wong VW, Amin NB, Takahashi H, Darekar A, Tacke F, Kiszko J, Rodriguez H, Nakajima A, Alkhouri N, Charlton M, Anstee QM

    Read Paper

  • A myeloid immunosuppressive phenotype defines Primary Refractoriness to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma

    A myeloid immunosuppressive phenotype defines Primary Refractoriness to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma

    Journal: J Hepatol. 2026 in press, accepted for publication, April 2026.

    Authors: Lombardi P*, Ramon-Gil*, Raja R, Brunett L, Manfredi GF, Zhou Z, Merces G, Cappuyns S, Fulgenzi CAM, D’Alessio A, Torkpour A, Celsa C, Stefanini B, Yang H, Crowley F, Marron TU, Saeed A, Pinter M, Scheiner B, Huang YH, Lee PC, Nishida N, Po-Ting Lin R, Dalbeni A, Vivaldi C, Masi G, Rohlen N, von Felden J, Kaseb A, Galle PR, Kudo M, Hsu WF, Rimassa L, Parisi A, Kelley RK, Toyoda H, Pirisi M, Jabar RF, Rakaee M, Cabibbo G, Cammà C, Piscaglia F, Hwang S, Shin DJ, Li M, Dekervel J, Guerra N, Meyer T, Reeves HL, Bengsch B, Daniele G, Mann DA, Chon HJ, Leslie, Pinato DJ



Awards

  1. NASH-DTA/ADVANCE (Accelerating Discovery: Actionable NASH Cirrhosis endpoints)

    Application of integrative multi-omics technologies to study the pathophysiology of cirrhosis and its downstream complications including hepatic decompensation and HCC. £20 million to Newcastle, Funder: Boehringer Ingelheim, PI Anstee. 2022 – 2028

  2. THRIVE project – Tumor-host interactions in liver cancer of childhood and adults

    Application of cuttingedge technologies to characterise the clinical/molecular determinant of liver cancer onset and progression. Funder: EU H2020 Mission Cancer, 12 million Euro. Newcastle 1.6 million Euro, PI Reeves, co-applicants Macdougal, Anstee, Cordell, Nsengimana, Jamieson. 2023-2028

  3. Manipulating neutrophils to achieve therapeutic refreshing of the immunosuppressed HCC microenvironment

    CRUK Programme Grant £1.8 million PI Mann, co-applicants Reeves, Leslie. 2023-2028

  4. LIVERAIM

    To incorporate AI for the development and validate a biomarker based screening platform, for early detection of liver fibrosis
    Funder: EU Innovative Health Initiative. 34.8 million Euro, 1 million Euro to Newcastle, Newcastle PI Anstee. 2024-2030

  5. CRUK Career Establishment Award

    “Targeting cancer-associated fibroblast responses to metabolic stress to overcome the immunosuppressed tumour niche in hepatocellular carcinoma” £1,012,209.28. PI Leslie. 2026-2032

Additional Resources

placeholder related links block LIVErNORTH: The Charity for Liver Patients

 

Theme Leadership and Contacts

  • Professor Quentin M Anstee

    Theme Co-Lead for Liver Disease, Multimorbidity and Lifestyle

  • A portrait photo of Helen Reeves

    Professor Helen Louise Reeves

    Theme Co-Lead for Liver Disease, Multimorbidity and Lifestyle 

  • A portrait photo of Stuart McPherson

    Professor Stuart McPherson

    BRC Theme Leadership Track for Liver Disease, Multimorbidity
    and Lifestyle, Consultant Hepatologist & Head of Department for Liver Medicine at the Newcastle Liver Unit

  • A portrait photo of Daniel Geh

    Dr Daniel Geh

    BRC Theme Leadership Track for Liver Disease, Multimorbidity and Lifestyle, NIHR Academic Clinical Fellow in Gastroenterology and Hepatology

More about the Theme

  • The Theme
  • Team
  • Impact
  • News and Events

Useful Links

Contact us

Our Impact

Acknowledgement

Accessibility Statement

Newcastle Biomedical Research Centre Logo in White

NIHR Newcastle Biomedical Research Centre
Biomedical Research Building
Campus for Ageing and Vitality
Newcastle upon Tyne
NE4 5PL
United Kingdom

Email: Newcastle.BRC@newcastle.ac.uk

Tel: +44(0)1912081148

The NIHR Newcastle Biomedical Research Centre (BRC) is part of the NIHR and hosted by The Newcastle upon Tyne Hospitals NHS Foundation Trust in partnership with Newcastle University, and Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust.

Newcastle upon Tyne Hospitals NHS Foundation Trust logo

Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust logo

Newcastle University Logo

Newcastle upon Tyne Hospitals NHS Foundation Trust logo

Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust logo

Newcastle University Logo

Privacy Policy

Cookie Policy

Website by Volute

Icon: This website is powered by 100% renewable energy
Icon: Click here to find out more
Cookies user preferences
We use cookies to ensure you to get the best experience on our website. If you decline the use of cookies, this website may not function as expected.
Accept all
Decline all
Read more
Analytics
Tools used to analyse the data to measure the effectiveness of a website and to understand how it works.
Google Analytics
Accept
Decline
Save preferences